Translation. Region: Russian Federal
Source: Moscow Government – Moscow Government –
An important disclaimer is at the bottom of this article.
On Moscow Industry Day, October 7, Sergei Sobyanin opened a new production complex of Generium-Next LLC (Pharmstandard group of companies) at the Alabushevo site of the Technopolis Moscow special economic zone (SEZ).
"I congratulate Moscow's industrialists on this holiday. There's much to celebrate—in recent years, Moscow's manufacturing sector has increased its output by 2.8 times, almost tripling. Every year, 100 to 150 new high-tech enterprises are registered in Moscow. Moscow's new industrialization is proceeding at a rapid pace, and Moscow is once again becoming a leader in manufacturing. This is especially important today, when our country needs technological independence," said Sergei Sobyanin.
According to the Moscow Mayor, one of the leading manufacturing sectors showing dynamic growth is the pharmaceutical industry. The city is home to over 300 pharmaceutical and medical device manufacturers, employing approximately 30,000 people.
"Moscow is the country's largest industrial center. Over the past 15 years, the capital's industrial output has grown 2.8-fold," Sergei Sobyanin wrote on his channel.
Source: Sergei Sobyanin's channel in MAX messenger
The capital's largest pharmaceutical cluster operates within the Technopolis Moscow Special Economic Zone. Eight production facilities are currently operating there, and a ninth—the state-of-the-art Generium-Next plant—has just opened. As Sergei Sobyanin noted at the opening, the new plant, producing vital medications, will supply not only Muscovites but also citizens across the country, as well as export medications. Significantly, much of the equipment is manufactured by domestic manufacturers.
Production complex "Generium-Next"
Construction of this production complex began in 2022 and was completed in October of this year. Investment in the project amounted to over 8.5 billion rubles.
A modern pharmaceutical facility covering 28,100 square meters was built on a 2.2-hectare plot of land. It will employ 250 people.
As of today, according to Alexander Andryushechkin, CEO of Generium-Next LLC, all commissioning work has been completed, and specialists are beginning to produce test series.
"Here, we plan to produce finished forms not only for the analogues that Generium was the first to register in Russia, but also next year, we will begin producing the finished form of the first Russian original drug for Hunter disease. We plan to continue our progress and, with Moscow's support, we hope to open two new production lines next year to increase capacity and create new jobs," noted Alexander Andryushechkin.
The new facility is designed to produce finished dosage forms of complex genetically engineered drugs for patients with orphan and other socially significant diseases. These include asthma, idiopathic urticaria, Gaucher disease, cystic fibrosis, cardiovascular diseases, as well as rare blood disorders and kidney disorders. The drugs will be manufactured using Russian-produced active ingredients. The facility's capacity will allow for the annual production of up to 5.4 million vials.
It is planned to produce such drugs as:
— "Tigerase", the world's first bioanalogue of dornase alfa, a mucolytic agent for the treatment of cystic fibrosis;
— Elizaria, the world’s first biosimilar to eculizumab, an immunosuppressant drug for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome;
— Genolar, the first biosimilar of omalizumab in Russia, a drug for the treatment of bronchial asthma and idiopathic urticaria;
— Glurazim, the first Russian biosimilar of imiglucerase, an enzyme drug for the treatment of Gaucher disease;
— Reveliza (Alteplase), the first biosimilar in Russia to alteplase, a fibrinolytic agent for the treatment of cardiovascular diseases.
The new facility is equipped with state-of-the-art technology. This includes domestically produced systems for preparing solutions for cytokine and monoclonal antibody production facilities, equipment for generating nitrogen gas, and systems for producing, storing, and distributing water—both purified and for injection.
As a resident of the Technopolis Moscow SEZ, Generium-Next receives significant tax and other benefits. SEZ residents are exempt from property, transport, and land taxes for 10 years. The corporate income tax rate is only two percent. A free customs zone regime is in effect, and land lease benefits are available. Upon completion of construction, residents have the option to purchase the leased land for one percent of its cadastral value.
The company has already begun producing test batches of the drug. Next, the production will need to obtain licensing from the Russian Ministry of Industry and Trade and registration certificates for the products in accordance with the requirements of the Russian Ministry of Health. Serial production is planned to begin by the end of 2026.
Once Generium-Next reaches full production capacity, it is expected that it will completely meet the needs for orphan drugs in Moscow and the country as a whole.
Moscow industry
Today, Moscow is the largest center of the Russian high-tech industry. The city is home to approximately 4,600 enterprises, employing 755,000 people—that's one in every 10 people working in the capital. Every year, 150 new innovative and high-tech manufacturing facilities open. By 2030, the number of industrial enterprises will increase to 5,500, and their employees to 850,000.
Moscow industry supplies its products to all regions of Russia and many countries around the world.
Compared to 2010, industrial production in the city's manufacturing sector has increased 2.8-fold. From January to August 2025, production growth was 5.7 percent compared to the same period last year.
The development of industry is facilitated by the strong scientific and educational base that has historically developed in Moscow. Today, in the R
Today, the capital's focus is on the development of pharmaceuticals and medical technology, microelectronics and instrumentation, space technology, electric vehicle manufacturing, the food industry, and other high-tech industries.
The capital's pharmaceutical industry
Moscow is one of Russia's largest producers of pharmaceuticals and medical devices. The city is home to over 300 companies, employing approximately 30,000 people.
Over the five years from 2020 to 2024, pharmaceutical production volumes increased 2.8-fold to 154 billion rubles. Moscow ranks second in Russia in terms of revenue in this industry.
The capital's pharmaceutical companies produce a wide range of medications, including modern drugs for the treatment of cancer and cardiovascular diseases, nervous system disorders, diabetes, painkillers, antibiotics, vaccines, and many others.
At the same time, the production of socially important medications is growing at an accelerated pace. For example, from January to August of this year, Moscow companies produced the following medications:
— for the treatment of gastrointestinal diseases — 5.8 million packages (a 7.4-fold increase compared to the same period last year);
— for the treatment of the cardiovascular system — 16.1 million packages (an increase of 2.3 times compared to the same period last year);
— serums and vaccines — 353.5 thousand packages (an increase of 10.5 percent compared to the same period last year).
By 2030, revenue from Moscow's pharmaceutical companies is projected to increase by 1.5 times, reaching 230 billion rubles, placing Moscow first in Russia in this indicator. Total investment in the pharmaceutical industry from 2020 to 2030 will amount to 191.5 billion rubles, including 109 billion rubles invested in industry development beginning in 2025.
A key component of the city's pharmaceutical industry is a cluster of companies operating within the Technopolis Moscow SEZ in Zelenograd and Pechatniki. The cluster was established in 2022 to develop research, development, and production capacity for import substitution of critically important drugs. It currently comprises 14 drug developers and manufacturers. Some companies are under construction, and eight have already launched production. All are residents of the Moscow special economic zone, receiving a range of tax incentives.
Among the cluster's key achievements are the first Russian drug for multiple sclerosis, a unique treatment for ankylosing spondylitis, innovative medications for inflammatory diseases and tumors, and a domestic analogue of Ozempic, a drug used to lower blood glucose levels and treat type 2 diabetes.
The cluster's participants' total operating production facilities exceed 173,000 square meters. More than 3,000 jobs have been created.
Cluster residents have already invested over 55 billion rubles in industrial development. The announced investment volume is double that (102.3 billion rubles). Plans call for an additional 47.3 billion rubles by 2030.
During its operations in the Technopolis Moscow SEZ, cluster participants received over five billion rubles in tax breaks. This means that for every ruble of tax breaks, there is 11 rubles of investment in the city's economy.
Operating enterprises of the cluster
PC-137 (Biocad biotechnology company) (43,000 square meters, 655 employees) produces medications for the treatment of socially significant diseases, including oncological and autoimmune diseases, including neurological and rheumatological ones. The company launched production of the first Russian original drug for the treatment of multiple sclerosis. The drug was registered by the Russian Ministry of Health in March 2023, and the company invested over one billion rubles in its development. Furthermore, in collaboration with a group of scientists from the Pirogov Russian National Research Medical University, the company developed an innovative drug for the treatment of ankylosing spondylitis. Its mechanism of action is unique and has no analogues anywhere in the world.
Velpharm-M (33,700 square meters, 968 employees) has established production of medications for the treatment of chronic renal failure, respiratory diseases, cardiac diseases, oncological diseases, and other conditions. Since 2019, medications for diabetes, cardiac disease therapy, anti-inflammatory and nonsteroidal antirheumatic drugs, as well as medications for idiopathic thrombocytopenic purpura, arterial hypertension, and a number of antiepileptic drugs have been launched.
R-Opra (R-Pharm Group) (30,600 square meters, 284 employees) develops medications for the treatment of oncological, autoimmune, asthmatic, and other diseases. This year, the company launched the first Russian generic version of a foreign drug based on a synthetic vitamin D analogue used to treat patients with severe forms of chronic kidney disease. It is included in the list of vital and essential drugs (VED).
Sputnik Technopolis (R-Pharm Group) (23,000 square meters, 457 employees) produced the Sputnik V vaccine and currently manufactures cancer treatments, as well as the world's first monoclonal antibody for rheumatoid arthritis (RA). It has a unique mechanism of action, specifically direct blockade of interleukin 6 (IL-6), a key mediator of acute inflammation. The drug has been approved by regulators in the Russian Federation, Azerbaijan, Kazakhstan, Kyrgyzstan, and the Republic of Belarus. It is patented in over 80 countries. In Russia, it is included in clinical guidelines for Rheumatoid Arthritis, the standard of care for adults with RA, COVID-19 treatment guidelines, and the list of vital and essential drugs.
Amedart (5,600 square meters, 328 employees) produces medications for the treatment of oncology, HIV, kidney failure, diabetes, rheumatoid arthritis, and transplantation. In 2022, the company launched import-substituting production of 26 new drugs within the Special Economic Zone (SEZ). The plant's capacity allows for the production of up to 15 million packages of these vital medications annually. Furthermore, the company will soon begin production of a medication for people with type 2 diabetes. This is a domestically produced and safer analogue of Ozempic, which will act like a hormone, reducing appetite and helping control blood sugar.
The cluster also includes the companies Biojet (area – 4.3 thousand square meters, 128 jobs), which produces drugs for the treatment of oncological diseases, and Rada-Pharma (area – 0.9 thousand square meters, 31 jobs), which produces products for the treatment of oncological, gynecological and dermatological diseases.
The Oncotarget company (4,000 square meters, employing 206 people) produces medications for the treatment of neurological, oncological, and other socially significant diseases. In March 2022, the first Russian drug for the rare disease malignant hyperthermia was registered.
Three operating enterprises of the cluster supply products under offset contracts (PK-137, Velpharm-M and R-Opra).
In total, the city has signed seven offset contracts with pharmaceutical cluster companies such as Biocad, R-Pharm (three offsets), Velpharm-M (two offsets), and Pharmasyntez. These companies will produce 125 international nonproprietary names (INNs) critically important to Russian healthcare. Of these, 45 INNs have not previously been produced in Russia. Specifically, the first offset contract in Russia was signed with Biocad for the creation of life-saving medications in Moscow. To implement the project, a 43,000-square-meter pharmaceutical production complex was built within the industrial cluster in the Special Economic Zone (SEZ), with the company's investment totaling 8.2 billion rubles. Since its launch, two million packages of finished products have been delivered to the city's healthcare facilities.
An offset contract was also signed with the Moscow Endocrine Plant (FSUE Endopharm), which has created additional production capacity for a wide range of antibacterial, analgesic, antidepressant, and antipsychotic medications. Under the contract, the plant supplies 20 medications.
The company recently registered a new intrathecal route for administering a well-known analgesic—a method of delivering the drug directly into the spinal canal. This allows for a powerful and lasting analgesic effect at a lower dose and significantly reduces side effects.
In addition, Endopharm Federal State Unitary Enterprise has begun production of another domestically produced analgesic, which will become a reliable tool for anesthesiologists and intensive care specialists. It provides a rapid and uniform effect with a predictable onset and offset, which is crucial for the safe conduct of medical procedures. All these medications help provide high-quality care to patients and maintain the country's pharmaceutical safety.
One of the important projects that FSUE Endopharm is implementing in Moscow is the production of drugs used in the treatment of infertility.
In October, construction of the Generium-Next plant (Pharmstandard Group) was completed at the Alabushevo site (area: 28,100 square meters, 250 jobs). This plant will produce modern genetically engineered drugs for the treatment of various diseases, including hereditary and rare ones.
That same month, a new facility, Artsellens (4,700 square meters, 41 jobs), was launched at the Pechatniki site. It plans to develop drugs for the treatment of a wide range of oncological diseases, including melanoma, Hodgkin's lymphoma, squamous cell carcinoma of the head and neck, cervical cancer, triple-negative breast cancer, urothelial cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, and others.
Construction and design work for five more production facilities is ongoing. These include:
— Plasma-Next (Pharmstandard Group of Companies) (area — 43 thousand square meters, 399 workplaces) — production of medicinal products from human blood plasma;
— Artsellens (Promomed Group of Companies) (area — 25.2 thousand square meters, 308 jobs) — production of biosimilar drugs for the treatment of oncological and autoimmune diseases;
— Skopinpharm (Pharmimex Group) (area — 13.5 thousand square meters, 184 workplaces) — creation of drugs for parenteral nutrition;
— Pharmasyntez (area — 2.5 thousand square meters, 36 workplaces) — production of antitumor drugs for the treatment of oncological diseases.
In addition, construction is underway on the second phase of the Velpharm-M plant (area – 33.8 thousand square meters, over a thousand jobs), which will produce drugs for the treatment of cancer and other socially significant diseases.
Thus, over the next few years, the amount of production space in the pharmaceutical cluster will double to approximately 300,000 square meters. Once the plants reach full capacity, the number of jobs will increase by 1.5 times to 4,400.
“The capacity being created will ensure Russia’s technological independence in the crucial area of pharmaceutical production,” Sergei Sobyanin wrote on his channel in
Source: Sergei Sobyanin's channel in MAX messenger
City support measures for pharmaceutical companies
The Moscow government provides a range of financial support measures to pharmaceutical companies, including granting industrial complex status. Currently, seven pharmaceutical companies have received this status, as well as the right to tax benefits stipulated by Moscow city legislation: Servier Rus LLC, Moscow Pharmaceutical Factory CJSC, Makiz-Pharma LLC, Moscow Endocrine Plant Federal State Unitary Enterprise, Binnopharm JSC, Biotiki Scientific and Production Company LLC, and Izvarino Pharma LLC.
Over the course of 10 years, the real estate tax for these enterprises will be 50 percent of the calculated amount, the land tax will be 20 percent of the calculated amount, and the land lease rate will be 0.3 percent of the cadastral value of the plot.
For example, over the past five years, Servier Rus' production volume has amounted to approximately 300 million packages of medicinal products, not only for the domestic market but also for export—over six million packages were exported internationally.
The plant's modernization allowed the launch of a high-tech tablet press for the production of heavier bilayer tablets, which is essential for the production of medications used to treat chronic venous diseases. Furthermore, the company expanded its portfolio and, in recent years, registered several breakthrough solutions in the fight against malignant diseases, such as acute lymphoblastic leukemia and metastatic pancreatic cancer.
Another support measure is a subsidy for equipment lease payments. This was received by the Moscow Endocrine Plant (over eight million rubles in 2022–2023) and Velpharm-M (over 117 million rubles in 2023–2024).
The city also provides preferential investment loans for the modernization and development of production. Since 2022, 19 Moscow pharmaceutical companies have received preferential investment loans totaling over 90 billion rubles through the Moscow Fund for Support of Industry and Entrepreneurship.
In particular, this year, Plasma-Next raised five billion rubles for the construction of a plant for the production of drugs from human blood plasma, and R-Pharm raised 400 million rubles for the acquisition of new production equipment.
In 2025, the maximum size of a preferential investment loan was increased from three to five billion rubles, and the loan term was increased from three to five years. Interest rate compensation for preferential investment loans is 50 percent of the key rate set by the Bank of Russia (currently 18 percent).
Financial support measures include the provision of land plots to organizations for lease at a preferential rate of one ruble per year. The Moscow government is transferring land plots to investors for the construction of pharmaceutical facilities as part of large-scale investment projects.
This year, Pharmstandard received a 15.5-hectare plot at a preferential rate of one ruble per year. A pharmaceutical production facility covering 109,000 square meters will be built in northeast Moscow, creating approximately 1,000 jobs. Investment in the project will total 13 billion rubles.
Alabushevo site of the Technopolis Moscow SEZ
Alabushevo is a rapidly developing site within the Technopolis Moscow Special Economic Zone, home to not only pharmaceutical companies but also photonics and microelectronics companies.
The total area of the commissioned facilities is 380,000 square meters of industrial, office, and laboratory space. Another 400,000 square meters of industrial buildings are under construction.
Today, the Alabushevo SEZ is home to 65 high-tech companies, creating jobs for 5,700 people. Total investment has exceeded 115 billion rubles.
One of the site's key projects is the Moscow Photonics Center, which is being implemented with the support of the Russian Ministry of Industry and Trade. Construction of the 26,700-square-meter center was completed in March of this year. It produces photonic integrated circuits (PICs), which enable data transfer rates to be increased by 50-100 times. This is crucial for telecommunications, space communications, as well as the development of artificial intelligence, biomedicine, and other high-tech industries. The PICs used in transceivers enable data transfer rates exceeding 100 gigabits per second while reducing power consumption by up to 10 times and device size by up to 20 times. Maximum production capacity is 100,000 units per year.
Another important project being implemented at the Alabushevo site is the construction of a photomask center. Moscow Government partners include the Russian Ministry of Industry and Trade, the Russian Ministry of Education and Science, and the National Research University "Moscow Institute of Electronic Technology." The center will cover 14,500 square meters, including approximately 3,000 square meters of cleanroom space. The facility will create approximately 300 jobs. The company's products will be photomasks used in the creation of integrated circuits. The center's capacity is designed to manufacture up to 5,500 photomasks per year.
Today, comprehensive improvement work continues at the Alabushevo site of the Technopolis Moscow special economic zone. Key attention is being paid to creating a user-friendly and intuitive environment. A digital navigation system is being implemented, making it easy to navigate the site using modern information panels and signs. To improve accessibility, bus routes No. 3 and 27 have been established, providing connections to the city center. A new road will also be built. It will connect Proektiruemy Proezd No. 5557 and Konstruktora Lukina Street, improving accessibility to the pharmaceutical cluster.
The plans include creating a park with trees, shrubs, and other plants, installing small architectural forms, and creating comfortable public spaces for outdoor recreation and work.
New sports and leisure complex
On October 7, a new road was opened on the territory of the Technopolis Moscow SEZ (Proektiruemy proezd No. 6029) sports and leisure complexAnyone can visit: employees of companies resident in the special economic zone and residents of nearby neighborhoods.
"Employees of SEZ resident companies, residents, and sports enthusiasts will have access to ice rinks, a football field with artificial turf, and six padel and squash courts. The complex also features a gym and dance studio, comfortable locker rooms with showers, a medical unit, and a refreshment bar. Classes in various sports will be held here, and sports tournaments are also planned," the Moscow Mayor wrote on his social media channel.
Source: Sergei Sobyanin's channel in MAX messenger
The building, with an area of approximately 17,000 square meters, houses a football field with artificial turf, two ice arenas, three padel tennis courts, and three squash courts.
The new sports and leisure complex in Zelenograd is expected to attract up to two thousand visitors per day.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.